Weekly intelligence on AI reshaping pharma and biotech — for the people making the decisions.https://gridchyn.ai/en-ushttps://gridchyn.ai/newsletter/2026-06-30-medra-autonomous-lab-darpa/https://gridchyn.ai/newsletter/2026-06-30-medra-autonomous-lab-darpa/Medra's Physical AI Lab pairs a multi-agent reasoning layer with DARPA funding and round-the-clock autonomous operation, reframing who generates AI training data in biology. Plus: RQ Bio's $115M flu antiviral Series A, why China — not the FDA — rattled BIO 2026, virtual-cell scaling laws, and The Onion Desk.Tue, 30 Jun 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-06-16-nvidia-open-models-molecular-glue/https://gridchyn.ai/newsletter/2026-06-16-nvidia-open-models-molecular-glue/At Fortune Brainstorm Tech, NVIDIA's healthcare chief reframes AI drug discovery's core constraint as regulatory acceptance, not scientific capability. Plus: Novartis expands its molecular-glue AI deal to $1.4B, Sanofi locks in Owkin for five years, and The Onion Desk.Tue, 16 Jun 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-06-09-sanofi-owkin-bms-ai-costs/https://gridchyn.ai/newsletter/2026-06-09-sanofi-owkin-bms-ai-costs/Sanofi becomes the second major pharma in three weeks to license Owkin's K Pro. BMS is now counting the bill on its 30,000-seat Claude rollout. Plus: 'first AI drug in the clinic' unpacked, the AI-funding bifurcation, and the Onion Desk.Tue, 09 Jun 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-06-02-allen-institute-brain-health-ai/https://gridchyn.ai/newsletter/2026-06-02-allen-institute-brain-health-ai/A $200M Brain Health Accelerator division applies the institute's cell-type atlases to gene therapies for Alzheimer's, Parkinson's, Huntington's, and ALS. Plus: Mayo AI at ASCO, an ex-Palantir team building pharma AI orchestration, and the week's autonomous-research debate.Tue, 02 Jun 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-05-26-bms-claude-ai-scientists/https://gridchyn.ai/newsletter/2026-05-26-bms-claude-ai-scientists/BMS deploys Claude Enterprise across 30,000+ employees as the unified agent layer. DeepMind's Co-Scientist and FutureHouse's Robin clear Nature peer review the same week Edison Scientific lands at Incyte. Plus: the EU AI Act high-risk draft, Helio × Syneos, and a Benchling adoption snapshot.Tue, 26 May 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-05-19-astrazeneca-owkin-fda-elsa-antibodies/https://gridchyn.ai/newsletter/2026-05-19-astrazeneca-owkin-fda-elsa-antibodies/Owkin's K Pro goes live inside AstraZeneca's competitive intelligence workflows. The FDA finishes consolidating 40+ systems into HALO and ships Elsa 4.0. Plus: the cell-free expression race, UVA's open drug-design suite, and four dispatches from The Onion Desk.Tue, 19 May 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-05-13-openbind-fda-novo-insilico/https://gridchyn.ai/newsletter/2026-05-13-openbind-fda-novo-insilico/The UK's OpenBind initiative takes aim at the structural data gap that's quietly limited AI drug discovery since AlphaFold. Also: the FDA's AI-triage inspection pilot, Novo's enterprise OpenAI bet, and Insilico's empirical case against general-purpose models.Wed, 13 May 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-04-30-isomorphic-owkin-data-moats/https://gridchyn.ai/newsletter/2026-04-30-isomorphic-owkin-data-moats/Isomorphic Labs gears up for human trials, Owkin's "AI scientist" lands at three top-ten pharmas, and Bessemer makes the case that biology-native data is the only durable advantage.Thu, 30 Apr 2026 00:00:00 GMThttps://gridchyn.ai/newsletter/2026-04-13-lilly-insilico/https://gridchyn.ai/newsletter/2026-04-13-lilly-insilico/Eli Lilly's record partnership with Insilico Medicine is the largest AI drug-discovery deal in history. Why now, what it actually buys, and what the second-derivative effects are.Mon, 13 Apr 2026 00:00:00 GMT